Hong Kong-listed TYK Medicines has claimed TY-9591, its third-generation EGFR inhibitor, outperformed AstraZeneca’s same-class blockbuster Tagrisso (osimertinib) in the first-line treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations.
Key Takeaways
- Investigator data from a head-to-head, pivotal Chinese Phase II trial show a “notable” improvement for TYK's TY-9591 as monotherapy over osimertinib, with both “statistical and clinical significance” in intracranial objective response rate in the first-line treatment of EGFR-mutated (exon 19 deletion and exon 21 L858R mutation) NSCLC with brain metastases.
- TYK has not yet disclosed if intracranial progression free survival, the trial's other primary endpoint, shows similar benefits over osimertinib
Investigator data from a head-to-head pivotal Phase II trial in Chinese patients show a “notable” improvement for TY-9591 over osimertinib as front-line monotherapy, with both “statistical and clinical significance” in intracranial objective response rate (iORR) in EGFR-mutated
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?